N
Nurix Therapeutics D
D
NRIX
16.880
USD
-0.15
(-0.88%)
مغلق
حجم التداول
30,050
الربح لكل سهم
-3
العائد الربحي
-
P/E
-6
حجم السوق
1,280,969,471
المقالات
العنوان: Nurix Therapeutics
القطاع: Healthcare
الصناعة: Biotechnology
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.